In medicine, endoscopic sleeve gastroplasty (ESG) is a minimally-invasive, non-surgical (incisionless), endoscopic weight loss procedure that is part of the field of endoscopic bariatric therapies. To perform ESG, a physician sutures a patient’s stomach into a narrower, smaller tube-like configuration.[1] The result is a more restricted stomach that forces patients to feel fuller sooner, eating fewer calories, which facilitates weight loss .[2][3][4]
History
Early iterations of endoscopic gastric remodeling for weight loss included the endoluminal vertical gastroplasty, which attempted to mimic the restricted stomach configuration of the vertical sleeve gastrectomy.[5] Around the same time, similar endoscopic remodeling along the stomach’s larger curvature was performed through tissue acquisition with a suction-based device, though this was limited by suture loss.[6][7] In 2012, Dr. Christopher Thompson, a Harvard Medical School professor and later Co-founder of Bariendo, performed the first ESG case in humans.[8] This was modified and tissue was acquired with a full-thickness suturing device, which has been the basis of the present ESG procedure.[9] In July 2022, the creation of the ESG using the Apollo Overstitch device was authorized by the United States Food and Drug Administration for the treatment of obesity in patients with a body mass index between 30–50 kg/m2.
Description
The ESG may be performed with slight variations by different physicians. It most commonly is performed using the Apollo ESG Device (formally Overstitch device). This device fits over a therapeutic double-channel endoscope to create a sutured row of stomach tissue. The tissue helix is advanced from the endoscope, put up against stomach tissue, and turned 2-4 rotations to access the gastric muscle layer. The helix is then retracted towards the scope, bringing the full-thickness acquired stomach tissue with it. Using the handle-operated needle driver, a needle attached to the suture wire is passed through the full-thickness tissue to the anchor exchange. This creates a full-thickness plication of stomach tissue. The needle is then passed back from the anchor exchange to the needle driver, and the process is repeated, threading the suture wire through each bite of stomach tissue. When enough full-thickness bites have been taken for a suture row, a cinch is passed through the scope over the suture. Typically, sutures are placed starting at the border of the antrum and gastric body at the incisura, then placed proximally up to the border of the gastric body and fundus. Each row of sutures can be a straight line or one of the variety of suture patterns reported in the literature, such as the “M,” “Z,” and “U” pattern as well as other novel patterns; nonetheless, to date, no suture pattern has been proven to be superior for weight loss.[10][11][12][13] Regardless of suture pattern, creation of the ESG focuses on tissue imbrication along the greater curvature of the stomach. The fundus is typically avoided due to the relatively thinner wall compared to the gastric body to avoid complications from the procedure.[14]
Providers and locations for ESG performance
Accredited advanced fellowship training programs in ESG and other endoscopic bariatric therapies are currently rare, and competency in ESG is typically achieved through proctoring by experts after completion of an accredited gastroenterology or surgical training program. Studies have reported that efficiency with performance of ESG and improved weight loss outcomes occur after approximately 35-38 cases.[15][16][17] Mastery was reported in one study to occur after 55 cases.[15] While early performance of the ESG has traditionally been carried out in university-affiliated/academic centers, ESG has been shown to be feasible and safe when performed in the community setting.[18]
Outcomes
The primary measures of weight loss outcomes for endoscopic bariatric therapies include total body weight loss (percentage of pre-procedure weight lost by a certain time point) and excess weight loss (percentage of pre-procedure weight above ideal body weight that is lost by a certain time point). The Preservation and Incorporation of Valuable Endoscopic Innovation thresholds is an expert panel with gastroenterologists and surgeons from the American Society for Gastrointestinal Endoscopy and The American Society for Metabolic and Bariatric Surgery, and in 2015, this panel recommended that any new endoscopic therapy for weight loss should have an excess weight loss exceeding 25% and a serious adverse event rate less than 5%.[19] Total body weight loss thresholds were not defined but are generally considered meaningful in novel endoscopic bariatric therapies if exceeding 5%.[20][21] Multiple studies of ESG have shown that this therapy satisfies these criteria, as outlined below.
Weight loss outcomes
Multicenter ESG Randomized Trial (MERIT)
The recently published MERIT study is the first and only randomized controlled trial of the ESG for treatment of obesity and included 209 adult subjects with class I and II obesity (BMI 30–40 kg/m2).[22] It was conducted from Dec. 2017 to Jun. 2019, spanned nine centers in the United States, and comprised 85 adults in the ESG arm and 124 adults in the control arm (lifestyle modification only). Subjects in the ESG arm lost 13.6% of body weight and 49.2% of excess body weight at one year, compared to 0.8% total body weight loss and 3.2% excess weight loss in the control arm at the same time point.
Weight loss
Prior to the MERIT study, numerous meta-analyses of studies on ESG report a total body weight loss of approximately 16% at one year.[23][24][25][26][27] Excess weight loss was observed to be approximately 60% at one year.[23][25][27][28] Weight loss reported from high volume community practices that have both expertise in ESG and robust longitudinal aftercare programs with dietitians have shown even greater outcomes, with total body weight loss approaching 30% and excess weight loss of 66% at one year.[18]
Predictors of greater weight loss
Patient selection is an important consideration for any weight loss therapy. The present published literature shows either no influence or conflicting results for patient age, sex, starting weight/BMI on weight loss from ESG. Long-term after care programs have demonstrated benefit for sustained weight loss after ESG, with one study showing that patients who continued after care visits following ESG had 20.5% total body weight loss compared to 16.9% total body weight loss in those who dropped out of long-term follow up programs.[29]
Weight-related comorbidities
There are over 200 obesity-related comorbidities, and it has been reported that achieving a total body weight loss of 10% has a significant impact of such conditions.[30] Thus, the weight loss outcomes with ESG are unsurprisingly accompanied by an improvement in several obesity-related comorbidities. Weight loss facilitated by ESG has been observed to bring about benefits in or even cure of diabetes/insulin sensitivity,[31][32][33]dyslipidemia,[31][32]blood pressure,[31] and fatty liver disease,[31][33][34] as well as quality of life.[35][36] The MERIT study showed 80% of patients who underwent ESG had improvement in one or more comorbidities at one year.[22]
Durability
Mid-term durability from ESG appears promising. A total body weight loss of 17% and excess weight loss of between approximately 60-67% was observed to be sustained at 18–24 months.[23][26][28] This was later confirmed in the multicenter, randomized controlled MERIT study, which observed that 68% of subjects who underwent an ESG maintained 25% or more of their excess weight loss at two years.[22] As a novel therapy, ESG presently lacks studies assessing long-term durability, though more data on this component of ESG are anticipated as more ESGs are performed over time. One recent study observed at 5 years from ESG that at least 10% total body weight loss was maintained in 90% of patients and at least 15% total body weight loss was maintained in 61% of patients.[17]
Safety
Mild to moderate gastrointestinal side effects (such as nausea, cramping, bloating, and abdominal discomfort) are common after ESG (reported in over 70% of patients), but these are predictable, temporary, and can be managed with medications.[25] Most will resolve within one week after ESG. Due to the minimally invasive nature of ESG, serious complications are rare. These include pain or nausea requiring hospitalization (1.08%); upper gastrointestinal tract bleeding (0.56%); peri-gastric leak or infected fluid collection (0.48%); pulmonary embolism (0.06%); perforation (0.06%).[23] Similar rates of serious adverse events were reported in the multicenter, randomized controlled MERIT study.[22] No deaths have been observed in the published ESG literature.
Physiologic mechanisms of weight loss from ESG
Peripheral appetite signaling/gastric sensorimotor function
Mechanisms of weight loss from ESG remains an area of active study. There are at least two mechanisms of peripheral appetite signaling thought to be mediated by ESG: first, increased sense of fullness during a meal leading to meal termination, potentially a result of the intact gastric fundus that serves as a food reservoir and the restriction to gastric expansion (accommodation) during a meal;[2][4] and second, from delayed emptying of the stomach, which promotes a prolonged sensation of fullness after a meal.[4]
Hunger and satiety hormones
Unlike the surgical sleeve gastrectomy, the ESG does not appear to affect central appetite signaling through the hunger hormone, ghrelin.[29] This is thought to be because the surgical sleeve removes the fundus, the primary site of ghrelin production, and the relatively thinner-walled fundus is avoided in the ESG for safety concerns. Furthermore, in cases where the fundus was sutured in ESG, this did not benefit weight loss outcomes.[14]
Further application of ESG with other weight loss treatments
Combination ESG and pharmacologic therapy
ESG can safely be combined with weight loss medications to improve weight loss or prevent weight regain after the procedure. The daily injectable medication liraglutide showed greater total body weight loss when combined with ESG compared to ESG alone at 7 months (approximately 25% vs 20% respectively).[14] Similar results are anticipated with other incretin agents, such as semaglutide and tirzepatide, though no studies have directly assessed these combinations.
ESG after surgical sleeve gastrectomy (Revisional ESG)
Weight regain after surgical sleeve gastrectomy has historically been managed with medications or a more invasive revisional surgery.[37][38][39][40] Recent data suggested that an ESG can safely be performed after the surgical sleeve gastrectomy (sometimes referred to as a “revisional ESG”), with total body weight loss of approximately 16-18% at 12 months.[41][42] While weight loss is not thought to be as robust as the initial weight loss surgery, the revisional ESG has an improved safety profile compared to a surgical revision and is therefore hypothesized to have greater patient acceptance.[37]
Comparison to laparoscopic sleeve gastrectomy
Laparoscopic sleeve gastrectomy (LSG) is one of the most common bariatric surgeries performed worldwide and shares a similar restricted stomach configuration with the ESG. However, it appears to operate with different weight loss mechanisms from the ESG, as it has been shown to reduce the hunger hormone ghrelin,[29][43] as well as accelerate, rather than delay, stomach emptying.[3]
Large, prospective studies directly comparing LSG to ESG are lacking. Comparison of the two therapies has relied on retrospective analysis and findings are conflicting. In a recent propensity score-matched study, the difference in weight loss for LSG vs ESG was 9.7% at 1 year, 6.0% at 2 years, and 4.8% at 3 years in favor of LSG, though the authors described the ESG as non-inferior based on an a priori definition of non-inferiority as being within 10% total body weight loss of the surgical arm.[44] Advantages of the ESG over LSG include lack of incisions, shorter length of stay (same-day-discharge vs 3 days in hospital);[29] less gastroesophageal reflux (0-2% vs 15-31%);[36][45] and lower morbidity and overall adverse event rate (1.9% vs 14.5%),[45][46] though some studies have presented similar rates of adverse events between ESG and LSG.[47][48] Despite less weight loss, one study found that patients who had undergone ESG had the same degree of comorbidity resolution and had higher quality of life scores at 6 months compared to those who had undergone LSG.[36]
^Fogel, Roberto; De Fogel, Juana; Bonilla, Ydaly; De La Fuente, Rafael (July 2008). "Clinical experience of transoral suturing for an endoluminal vertical gastroplasty: 1-year follow-up in 64 patients". Gastrointestinal Endoscopy. 68 (1): 51–58. doi:10.1016/j.gie.2007.10.061. ISSN0016-5107. PMID18355825.
^Brethauer, Stacy A.; Chand, Bipan; Schauer, Philip R.; Thompson, Christopher C. (November 2010). "Transoral gastric volume reduction for weight management: technique and feasibility in 18 patients". Surgery for Obesity and Related Diseases. 6 (6): 689–694. doi:10.1016/j.soard.2010.07.012. ISSN1550-7289. PMID20947451.
^Brethauer, Stacy A.; Chand, Bipan; Schauer, Philip R.; Thompson, Christopher C. (May 2012). "Transoral gastric volume reduction as intervention for weight management: 12-month follow-up of TRIM trial". Surgery for Obesity and Related Diseases. 8 (3): 296–303. doi:10.1016/j.soard.2011.10.016. ISSN1550-7289. PMID22178565.
^ abSaumoy, Monica; Schneider, Yecheskel; Zhou, Xi Kathy; Shukla, Alpana; Kahaleh, Michel; Aronne, Louis; Sharaiha, Reem Z. (February 2018). "A single-operator learning curve analysis for the endoscopic sleeve gastroplasty". Gastrointestinal Endoscopy. 87 (2): 442–447. doi:10.1016/j.gie.2017.08.014. ISSN0016-5107. PMID28843586.
^Bhandari, Mohit; Jain, Saransh; Mathur, Winni; Kosta, Susmit; Neto, Manoel Galvao; Brunaldi, Vitor Ottoboni; Fobi, Mathias (November 2019). "Endoscopic sleeve gastroplasty is an effective and safe minimally invasive approach for treatment of obesity: First Indian experience". Digestive Endoscopy. 32 (4): 541–546. doi:10.1111/den.13508. ISSN0915-5635. PMID31394006. S2CID199506564.
^ abSharaiha, Reem Z.; Hajifathalian, Kaveh; Kumar, Rekha; Saunders, Katherine; Mehta, Amit; Ang, Bryan; Skaf, Daniel; Shah, Shawn; Herr, Andrea; Igel, Leon; Dawod, Qais; Dawod, Enad; Sampath, Kartik; Carr-Locke, David; Brown, Robert (May 2021). "Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity". Clinical Gastroenterology and Hepatology. 19 (5): 1051–1057.e2. doi:10.1016/j.cgh.2020.09.055. ISSN1542-3565. PMID33011292. S2CID222144445.
^ abJames, Theodore W.; Reddy, Sumana; Vulpis, Trish; McGowan, Christopher E. (2019-12-18). "Endoscopic Sleeve Gastroplasty Is Feasible, Safe, and Effective in a Non-academic Setting: Short-Term Outcomes from a Community Gastroenterology Practice". Obesity Surgery. 30 (4): 1404–1409. doi:10.1007/s11695-019-04331-3. ISSN0960-8923. PMID31853865. S2CID209418685.
^Abu Dayyeh, Barham K.; Kumar, Nitin; Edmundowicz, Steven A.; Jonnalagadda, Sreenivasa; Larsen, Michael; Sullivan, Shelby; Thompson, Christopher C.; Banerjee, Subhas (September 2015). "ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies". Gastrointestinal Endoscopy. 82 (3): 425–438.e5. doi:10.1016/j.gie.2015.03.1964. ISSN0016-5107. PMID26232362.
^Abu Dayyeh, Barham K; Maselli, Daniel B; Rapaka, Babusai; Lavin, Thomas; Noar, Mark; Hussan, Hisham; Chapman, Christopher G; Popov, Violeta; Jirapinyo, Pichamol; Acosta, Andres; Vargas, Eric J; Storm, Andrew C; Bazerbachi, Fateh; Ryou, Marvin; French, Matthew (November 2021). "Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial". The Lancet. 398 (10315): 1965–1973. doi:10.1016/s0140-6736(21)02394-1. ISSN0140-6736. PMID34793746. S2CID244127807.
^ abcdAbu Dayyeh, Barham K; Bazerbachi, Fateh; Vargas, Eric J; Sharaiha, Reem Z; Thompson, Christopher C; Thaemert, Bradley C; Teixeira, Andre F; Chapman, Christopher G; Kumbhari, Vivek; Ujiki, Michael B; Ahrens, Jeanette; Day, Courtney; Galvao Neto, Manoel; Zundel, Natan; Wilson, Erik B (August 2022). "Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial". The Lancet. 400 (10350): 441–451. doi:10.1016/s0140-6736(22)01280-6. ISSN0140-6736. PMID35908555. S2CID251152812.
^ abcdHedjoudje, Abdellah; Abu Dayyeh, Barham K.; Cheskin, Lawrence J.; Adam, Atif; Neto, Manoel Galvão; Badurdeen, Dilhana; Morales, Javier Graus; Sartoretto, Adrian; Nava, Gontrand Lopez; Vargas, Eric; Sui, Zhixian; Fayad, Lea; Farha, Jad; Khashab, Mouen A.; Kalloo, Anthony N. (May 2020). "Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis". Clinical Gastroenterology and Hepatology. 18 (5): 1043–1053.e4. doi:10.1016/j.cgh.2019.08.022. ISSN1542-3565. PMID31442601. S2CID201632114.
^Jalal, Md Asif; Cheng, Qiuye; Edye, Michael B. (2020-04-17). "Systematic Review and Meta-Analysis of Endoscopic Sleeve Gastroplasty with Comparison to Laparoscopic Sleeve Gastrectomy". Obesity Surgery. 30 (7): 2754–2762. doi:10.1007/s11695-020-04591-4. ISSN0960-8923. PMID32304011. S2CID215795312.
^ abde Miranda Neto, Antonio Afonso; de Moura, Diogo Turiani Hourneaux; Ribeiro, Igor Braga; Khan, Ahmad; Singh, Shailendra; da Ponte Neto, Alberto Machado; Madruga Neto, Antonio Coutinho; do Monte Junior, Epifanio Silvino; Tustumi, Francisco; Bernardo, Wanderley Marques; de Moura, Eduardo Guimarães Hourneaux (2020-02-27). "Efficacy and Safety of Endoscopic Sleeve Gastroplasty at Mid Term in the Management of Overweight and Obese Patients: a Systematic Review and Meta-Analysis". Obesity Surgery. 30 (5): 1971–1987. doi:10.1007/s11695-020-04449-9. ISSN0960-8923. PMID32107706. S2CID211539809.
Abu Dayyeh, B. K. et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet400, 441–451 (2022).
James, T. W., Reddy, S., Vulpis, T. & McGowan, C. E. Endoscopic Sleeve Gastroplasty Is Feasible, Safe, and Effective in a Non-academic Setting: Short-Term Outcomes from a Community Gastroenterology Practice. Obes Surg30, 1404–1409 (2020).
Endapan beralih ke halaman ini. Untuk kegunaan lain, lihat Endapan (disambiguasi). Reaksi pengendapan Reaksi pengendapan adalah suatu jenis reaksi yang dapat berlangsung dalam cairan, misalnya air. Suatu reaksi dapat dikatakan reaksi pengendapan apabila reaksi tersebut menghasilkan endapan. Endapan yaitu zat padat yang tidak larut dalam cairan tersebut. Senyawa-senyawa yang sering digunakan dalam reaksi pengendapan yaitu senyawa-senyawa ionik. Sebagai contoh reaksi antara larutan timbal nitra...
Antonio Mije GarcíaBorn(1905-09-24)24 September 1905SevilleDied1 September 1976(1976-09-01) (aged 70)ParisNationalitySpanishOccupation(s)Baker, union leaderKnown forSpanish Civil War politics Antonio Mije García (24 September 1905 – 1 September 1976) was a member of the Spanish Communist Party who became a deputy for Seville in the Second Spanish Republic. He served in various senior positions during the Spanish Civil War (1936–39). After the war he lived in France, Mexico and...
Former internment camp near Waipahu, Hawaii Honouliuli National Historic SiteLocation of Honouliuli National Historic Site in HawaiiCoordinates21°23′30″N 158°3′35″W / 21.39167°N 158.05972°W / 21.39167; -158.05972[1]Area122.5 acres (49.6 ha)[2]Built1943 (1943)Governing bodyNational Park ServiceWebsiteHonouliuli National Historic Site U.S. National Historic SiteOfficial nameHonouliuli National Historical SiteDesignatedFebruary 19, 20...
Prime Minister of GrenadaFlag of GrenadaIncumbentDickon Mitchellsince 24 June 2022StyleThe HonourableAppointerThe Governor-Generalon behalf of the MonarchTerm lengthAt His Majesty's pleasurePrecursorPremier of GrenadaInaugural holderEric GairyFormation7 February 1974First holderEric GairySalary80,619 Eastern Caribbean dollars/29,859 USD annually[1] Politics of Grenada Executive Monarch (list) King Charles III Governor-General (list) Dame Cécile La Grenade Prime Minister Dickon M...
Ayoka Ayo ChenziraBorn (1953-11-08) November 8, 1953 (age 70)Philadelphia, PennsylvaniaNationalityAmericanOccupation(s)Filmmaker and Television DirectorYears active1979 -Known forOne of a handful of Black experimental filmmakers working in the late 1970s, One of the first African American women filmmakers to write, produce, and direct a feature filmNotable workHairpiece: A Film for Nappyheaded People, Zajota & the Boogie Spirit, Alma's Rainbow, MOTV, HERadventure Ayoka Ayo ...
This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. Please help to improve this article by introducing more precise citations. (August 2011) (Learn how and when to remove this template message) August ŠenoaStjepan Horvat wearing the Iron Cross and the Honour Roll Clasp as an Air Force lieutenant in Zagreb, 1942[1]Born(1895-11-29)November 29, 1895Karlowitz, Kingdom of Croatia-Slavonia, Austri...
Legendary king of the Britons Brutus Greenshield from the Genealogical Chronicle of the Kings of England to Edward IV (c. 1461) Brutus Greenshield (Welsh: Brutus Darian Las) was a legendary king of the Britons as accounted by Geoffrey of Monmouth. He was the son of King Ebraucus. Geoffrey's account According to Geoffrey, Brutus, called Greenshield (Latin: Viridescutum), was the eldest of twenty sons and the only remaining son of Ebraucus in Britain at the time of his death. All Ebraucus...
Artikel ini tidak memiliki referensi atau sumber tepercaya sehingga isinya tidak bisa dipastikan. Tolong bantu perbaiki artikel ini dengan menambahkan referensi yang layak. Tulisan tanpa sumber dapat dipertanyakan dan dihapus sewaktu-waktu.Cari sumber: Albert Eduard Stoové – berita · surat kabar · buku · cendekiawan · JSTORAlbert Eduard StoovéPengabdian Hindia BelandaLama dinas1939-19461954-1976PangkatSersanKesatuan2-VLG-V334 SquadronPerang/pert...
English actor (1921–2003) This article is about the British actor. For the American actor, see Robert Brown (American actor). This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Robert Brown British actor – news · newspapers · books · scholar · JSTOR (March 2013) (Learn how and when to remove this templat...
Robert Emmett O'ConnorO'Connor (kanan) pada kartu lobi untuk Our Blushing Brides (1930)Lahir(1885-03-18)18 Maret 1885Milwaukee, Wisconsin, Amerika SerikatMeninggal4 September 1962(1962-09-04) (umur 77)Hollywood, California, Amerika SerikatTahun aktif1919-1950 Robert Emmett O'Connor (18 Maret 1885 – 4 September 1962) adalah seorang pemeran film Amerika Serikat.[1] Ia tampil dalam lebih dari 200 film antara 1919 dan 1950. Filmografi pilihan Pay Your Dues (1919 ...
Стратегічні ракетні війська Корейської народної армії Країна Північна КореяНалежність Kim Jong-un[1]Вид IndependentТип Strategic missile forceРоль Strategic deterrenceЧисельність UnknownГарнізон/Штаб Sŏngch'ŏn-kunSouth Pyongan, North KoreaКомандуванняКомандуючий генерал-лейтенант Кім Рак-гйом Медіафайли на В...
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Music Ka Maha Muqqabla – news · newspapers · books · scholar · JSTOR (August 2016) (Learn how and when to remove this template message) Indian TV series or programme Music Ka Maha MuqqablaGenreGame showCreated byGajendra SinghDeveloped byGajendra SinghDire...
Highway in Ukraine Highway H28Автошлях Н28Route informationLength71.4 km (44.4 mi)Existed9 August 2017–presentMajor junctionssouth end M 01 in Chernihivnorth endBelarusian border at Senkivka LocationCountryUkraineOblastsChernihiv Highway system Roads in Ukraine State Highways Senkivka border crossing H28 is a national road (H-Highway) in Chernihiv Oblast, Ukraine. It runs north-south and connected Chernihiv with a tri-side border.[1] Before 2017, H2...
Swedish Championship league in women's ice hockey Swedish Women's Hockey LeagueSvenska damhockeyligan (Swedish) Current season, competition or edition: 2023–24 SDHL seasonFormerlyRiksserien (2007–2016)SportIce hockeyFounded2007 (2007)FounderSwedish Ice Hockey AssociationInaugural season2007–08PresidentAgne BengtssonNo. of teams10Country SwedenMost recentchampion(s)Luleå HF/MSSK (2022–23)Most titlesLuleå HF/MSSK (6)TV partner(s)C More Sport, SVTRelegation toNDHLRelated...
Municipality in Cavite, Philippines This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Noveleta – news · newspapers · books · scholar · JSTOR (October 2013) (Learn how and when to remove this template message) Municipality in Calabarzon, PhilippinesNoveleta Tierra AltaMunicipalityMunicipality of Noveleta(From t...
Adrian Mutu Mutu nel 2007 Nazionalità Romania Altezza 180 cm Peso 74 kg Calcio Ruolo Allenatore (ex attaccante) Squadra CFR Cluj Termine carriera 20 maggio 2016 - giocatore Carriera Giovanili 1992-1996 Argeș Pitești Squadre di club1 1996-1998 Argeș Pitești41 (11)1998-2000 Dinamo Bucarest33 (22)2000 Inter10 (0)2000-2002 Verona57 (16)2002-2003 Parma31 (18)2003-2004 Chelsea27 (6)2005-2006 Juventus33 (7)2006-2011 Fiorentina112 (54)201...
British physician and academic This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: Thomas G. Pickering – news · newspapers · books · scholar · JSTOR (August 2017) (Learn how and when to remove this template message) Thomas G. Pickering (1940 – 2009) was a British physician and academic. He was a professor of medicine at College of Physicians and Surgeons,...
У Вікіпедії є статті про інших людей із прізвищем Пришляк. Євген Пришляк Крайовий провідник ОУН Львівського краю Загальна інформаціяНародження 13 грудня 1913(1913-12-13)м. Миколаїв тепер Львівська областьСмерть 3 грудня 1987(1987-12-03) (73 роки)м. Миколаїв, Львівська областьПоховання Л...
João MunizDatos personalesNacimiento Ribeira Brava, Portugal26 de junio de 2005 (19 años)Nacionalidad(es) PortuguesaAltura 1,90 m (6′ 3″)Carrera deportivaDeporte FútbolClub profesionalDebut deportivo 2022(Sporting de Lisboa B)Club Sporting de Lisboa BLiga Terceira LigaPosición DefensaDorsal(es) 43Goles en clubes 1Trayectoria Sporting de Lisboa B (2022-presente)[editar datos en Wikidata] João António Nascimento Muniz (Ribeira Brava, Portugal, 26 de junio de 2005) es un...
Claire ForlaniClaire ForlaniLahirClaire Antonia Forlani01 Juli 1972 (umur 51)Twickenham, London, InggrisNama lainClair ForlaniPendidikanArts Educational Schools, LondonPekerjaanAktrisTahun aktif1991–sekarangSuami/istriDougray Scott (m. 2007) Claire Antonia Forlani (lahir 1 Juli 1972) adalah seorang aktris berkebangsaan Inggris. Dia menjadi terkenal saat bermain di film utamanya seperti Meet Joe Black dengan Brad Pitt. Dia dilahirkan di London. ...
Strategi Solo vs Squad di Free Fire: Cara Menang Mudah!